Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Chronic Heart Failure With Preserved Ejection Fraction

Drug Information

Target Indication

Chronic Heart Failure With Preserved Ejection Fraction

Clinical Trial

Last updated: 1/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

BAYRY

BAYER

Related Pipeline

Acute Coronary Syndrome

Overactive Bladder

Pneumonia, Bacterial

Chronic Kidney Disease

Colorectal Neoplasms